{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,6]],"date-time":"2026-01-06T13:19:31Z","timestamp":1767705571643},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T00:00:00Z","timestamp":1481760000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>A certain number of studies have showed that p53 gene transfer has an anti-tumor activity <jats:italic>in vitro<\/jats:italic> and <jats:italic>in vivo<\/jats:italic>. This study was to evaluate the efficacy and safety of thoracic perfusion of recombinant human adenovirus p53 (rAd-p53, Gendicine) for controlling malignant pleural effusion (MPE). We searched for the relevant studies from the database of MEDLINE, Web of Science, EMBASE, Cochrance Library and CNKI to collect the trials concerning the efficacy and safety of rAd-p53 to treat MPE. Fourteen randomised controlled trials (RCTs) with 879 patients were involved in this analysis. The rAd-p53 combined with chemotherapeutic agents significantly improved the overall response rate (ORR) (P\u2009&lt;\u20090.001; odds ratio\u2009=\u20093.73) and disease control rate (DCR) (P\u2009&lt;\u20090.001; odds ratio\u2009=\u20092.32) of patients with MPE as well as the quality of life (QOL) of patients (P\u2009&lt;\u20090.001; odds ratio\u2009=\u20094.27), compared with that of chemotherapeutic agents alone. In addition, the participation of rAd-p53 did not have an obvious impact on the most of incidence of adverse reactions (AEs) (P\u2009&lt;\u20090.05) except the fever (P\u2009&lt;\u20090.001). However, the fever was self-limited and could be tolerated well. The application of rAd-p53 through thoracic perfusion for treating MPE had a better efficacy and safety, which could be a potential choice for controlling MPE.<\/jats:p>","DOI":"10.1038\/srep39355","type":"journal-article","created":{"date-parts":[[2016,12,15]],"date-time":"2016-12-15T13:27:37Z","timestamp":1481808457000},"update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Evaluation of efficacy and safety for recombinant human adenovirus-p53 in the control of the malignant pleural effusions via thoracic perfusion"],"prefix":"10.1038","volume":"6","author":[{"given":"Rong","family":"Biaoxue","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pan","family":"Hui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gao","family":"Wenlong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yang","family":"Shuanying","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,12,15]]},"reference":[{"key":"BFsrep39355_CR1","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1111\/1759-7714.12271","volume":"7","author":"T Ebata","year":"2016","unstructured":"Ebata, T. et al. Retrospective analysis of unknown primary cancers with malignant pleural effusion at initial diagnosis. Thorac Cancer 7, 39\u201343, doi: 10.1111\/1759-7714.12271 (2016).","journal-title":"Thorac Cancer"},{"key":"BFsrep39355_CR2","doi-asserted-by":"crossref","unstructured":"Yang, J. et al. Diagnostic and prognostic significance of receptor-binding cancer antigen expressed on SiSo cells in lung-cancer-associated pleural effusion. Clin Respir J, doi: 10.1111\/crj.12527 (2016).","DOI":"10.1111\/crj.12527"},{"key":"BFsrep39355_CR3","doi-asserted-by":"crossref","unstructured":"Wong, W. M. et al. Managing malignant pleural effusion with an indwelling pleural catheter: factors associated with spontaneous pleurodesis. Hong Kong Med J, doi: 10.12809\/hkmj154673 (2016).","DOI":"10.12809\/hkmj154673"},{"key":"BFsrep39355_CR4","doi-asserted-by":"publisher","first-page":"33","DOI":"10.4103\/2278-330x.179701","volume":"5","author":"R Mir","year":"2016","unstructured":"Mir, R. et al. Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients. South Asian J Cancer 5, 33\u201336, doi: 10.4103\/2278-330x.179701 (2016).","journal-title":"South Asian J Cancer"},{"key":"BFsrep39355_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1517\/14712598.2010.484801","volume":"10","author":"AA Chiappori","year":"2010","unstructured":"Chiappori, A. A., Soliman, H., Janssen, W. E., Antonia, S. J. & Gabrilovich, D. I. INGN-225: a dendritic cell-based p53 vaccine (Ad.p53-DC) in small cell lung cancer: observed association between immune response and enhanced chemotherapy effect. Expert Opin Biol Ther 10, 983\u2013991, doi: 10.1517\/14712598.2010.484801 (2010).","journal-title":"Expert Opin Biol Ther"},{"key":"BFsrep39355_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1177\/021849230701500108","volume":"15","author":"C Gebitekin","year":"2007","unstructured":"Gebitekin, C., Bayram, A. S., Tunca, B. & Balaban, S. A. Clinical significance of p53 gene mutation in T1-2N0 non-small cell lung cancer. Asian Cardiovasc Thorac Ann 15, 35\u201338 (2007).","journal-title":"Asian Cardiovasc Thorac Ann"},{"key":"BFsrep39355_CR7","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1016\/j.clon.2013.09.003","volume":"26","author":"X Liu","year":"2014","unstructured":"Liu, X. et al. Association between smoking and p53 mutation in lung cancer: a meta-analysis. Clin Oncol (R Coll Radiol) 26, 18\u201324, doi: 10.1016\/j.clon.2013.09.003 (2014).","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"BFsrep39355_CR8","first-page":"678","volume":"27","author":"CZ Zhou","year":"2004","unstructured":"Zhou, C. Z., Li, Y. & Xu, J. Correlation between p53 gene mutation and the expression of tumor drug resistance genes in lung cancer and its clinical significance. Zhonghua Jie He He Hu Xi Za Zhi 27, 678\u2013682 (2004).","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"BFsrep39355_CR9","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/S1055-3207(02)00028-5","volume":"11","author":"SG Swisher","year":"2002","unstructured":"Swisher, S. G. & Roth, J. A. Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am 11, 521\u2013535 (2002).","journal-title":"Surg Oncol Clin N Am"},{"key":"BFsrep39355_CR10","doi-asserted-by":"publisher","first-page":"2197","DOI":"10.3892\/or.2013.2384","volume":"29","author":"Y Cun","year":"2013","unstructured":"Cun, Y. et al. Combined use of adenoviral vector Ad5\/F35-mediated APE1 siRNA enhances the therapeutic efficacy of adenoviral-mediated p53 gene transfer in hepatoma cells in vitro and in vivo. Oncol Rep 29, 2197\u20132204, doi: 10.3892\/or.2013.2384 (2013).","journal-title":"Oncol Rep"},{"key":"BFsrep39355_CR11","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1269\/jrr.11110","volume":"53","author":"WS Koom","year":"2012","unstructured":"Koom, W. S. et al. Combination of radiotherapy and adenovirus-mediated p53 gene therapy for MDM2-overexpressing hepatocellular carcinoma. J Radiat Res 53, 202\u2013210 (2012).","journal-title":"J Radiat Res"},{"key":"BFsrep39355_CR12","doi-asserted-by":"publisher","first-page":"529","DOI":"10.3892\/ol.2012.747","volume":"4","author":"JT Ma","year":"2012","unstructured":"Ma, J. T. et al. Synergistic cytotoxic effects of recombinant human adenovirus p53 and radiation at various time points in A549 lung adenocarcinoma cells. Oncol Lett 4, 529\u2013533, doi: 10.3892\/ol.2012.747 (2012).","journal-title":"Oncol Lett"},{"key":"BFsrep39355_CR13","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.3892\/ol.2014.2811","volume":"9","author":"JS Qi","year":"2015","unstructured":"Qi, J. S., Wang, W. H. & Li, F. Q. Combination of interventional adenovirus-p53 introduction and ultrasonic irradiation in the treatment of liver cancer. Oncol Lett 9, 1297\u20131302, doi: 10.3892\/ol.2014.2811 (2015).","journal-title":"Oncol Lett"},{"key":"BFsrep39355_CR14","doi-asserted-by":"publisher","first-page":"526","DOI":"10.3892\/or.2014.3665","volume":"33","author":"X Wang","year":"2015","unstructured":"Wang, X. et al. Ad-p53 enhances the sensitivity of triple-negative breast cancer MDA-MB-468 cells to the EGFR inhibitor gefitinib. Oncol Rep 33, 526\u2013532, doi: 10.3892\/or.2014.3665 (2015).","journal-title":"Oncol Rep"},{"key":"BFsrep39355_CR15","first-page":"849","volume":"84","author":"XZ Zhang","year":"2004","unstructured":"Zhang, X. Z. et al. Quality control of clinical-grade recombinant adenovirus used in gene therapy. Zhonghua Yi Xue Za Zhi 84, 849\u2013852 (2004).","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"BFsrep39355_CR16","first-page":"192","volume":"24","author":"T Bo","year":"2015","unstructured":"Bo, T. et al. Recombined adenovirus expressing P53 in the treatment of malignant pleural effusion with lung cancer (in Chinese). J Reg Anat Oper Surg 24, 192\u2013194 (2015).","journal-title":"J Reg Anat Oper Surg"},{"key":"BFsrep39355_CR17","first-page":"5","volume":"9","author":"Z Chengzhi","year":"2011","unstructured":"Chengzhi, Z., Ouyuan, M., Shiyue, L. & Huo, T. Clinical study on treatment of 96 lung cancer patients with malignant pleural effusion (in Chinese). Guide of China Medicine 9, 5\u20137 (2011).","journal-title":"Guide of China Medicine"},{"key":"BFsrep39355_CR18","first-page":"1481","volume":"18","author":"L Dong","year":"2013","unstructured":"Dong, L. Clinical observation of gene therapy combined with chemotherapy in the treatment of malignant pleural effusion caused by lung carcinoma (in Chinese). Journal of Clinical Pulmonary Medicine 18, 1481\u20131482 (2013).","journal-title":"Journal of Clinical Pulmonary Medicine"},{"key":"BFsrep39355_CR19","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1177\/147323000803600614","volume":"36","author":"M Dong","year":"2008","unstructured":"Dong, M. et al. Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. J Int Med Res 36, 1273\u20131278 (2008).","journal-title":"J Int Med Res"},{"key":"BFsrep39355_CR20","first-page":"213","volume":"35","author":"Z Lin","year":"2015","unstructured":"Lin, Z., Jiqian, W. & Li, W. Efficacy of recombinant human Ad-p53 injection combined hyperthermia chemotherapy in treating 41 cases malignant pleural effusion of NSCLC (in Chinese). Chinese Journal of Gerontology 35, 213\u2013214 (2015).","journal-title":"Chinese Journal of Gerontology"},{"key":"BFsrep39355_CR21","first-page":"2996","volume":"40","author":"T Ling","year":"2011","unstructured":"Ling, T. & Ying, X. Efficacy observation on recombinant human Ad- p53 injection combined with cisplatin for malignant pleural effusion (in Chinese). Chongqing Medicine 40, 2996\u20132997 (2011).","journal-title":"Chongqing Medicine"},{"key":"BFsrep39355_CR22","first-page":"1120","volume":"21","author":"Y Nanchang","year":"2010","unstructured":"Nanchang, Y. & Xiaodong, W. Efficacy observation on recombinant human Ad- p53 injection combined with cisplatin for malignant pleural effusion of non- small- cell lung cancer with intracavitary administration (in Chinese). China Pharmacy 21, 1120\u20131122 (2010).","journal-title":"China Pharmacy"},{"key":"BFsrep39355_CR23","first-page":"896","volume":"16","author":"Z Rong","year":"2011","unstructured":"Rong, Z., Liang, C. & Zili, M. Clinical research on recombinant human Ad-p53 pleural injection combined with cisplatin in treatment of non-small cell lung cancer with malignant pleural effusion (in Chinese). Journal of Clinical Pulmonary Medicine 16, 896\u2013898 (2011).","journal-title":"Journal of Clinical Pulmonary Medicine"},{"key":"BFsrep39355_CR24","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.5732\/cjc.009.10149","volume":"28","author":"Z Weizhu","year":"2009","unstructured":"Weizhu, Z., Jikun, W., Wei, L. & Xiuli, Z. Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer (in Chinese). Chinese Journal of Cancer 28, 1324\u20131327 (2009).","journal-title":"Chinese Journal of Cancer"},{"key":"BFsrep39355_CR25","first-page":"188","volume":"17","author":"W Xiaohong","year":"2014","unstructured":"Xiaohong, W., Juanquan, Y. & Guohuan, L. Clinical observation of recombinational human p53 adenovirus injection combined with chemotherapy in treatment of malignant pleural effusion (in Chinese). Chinese Journal of Coal Industry Medicine 17, 188\u2013191 (2014).","journal-title":"Chinese Journal of Coal Industry Medicine"},{"key":"BFsrep39355_CR26","first-page":"87","volume":"26","author":"Z Yanliang","year":"2011","unstructured":"Yanliang, Z. & Yun, M. Efficacy observation on recombinant human Ad- p53 injection combined with cisplatin for lung cancer with malignant pleural effusion (in Chinese). Practical Journal of Cancer 26, 87\u201388 (2011).","journal-title":"Practical Journal of Cancer"},{"key":"BFsrep39355_CR27","first-page":"594","volume":"10","author":"Q Yimei","year":"2011","unstructured":"Yimei, Q., Guoqing, L. & Hongmei, W. Clinical research on recombinant human Ad p53 injection combined with continuous heperthermic perfusion in treatment of malignant pleural effusion induced by lung cancer (in Chinese). Chin J Diffic and Compl Cas 10, 594\u2013596 (2011).","journal-title":"Chin J Diffic and Compl Cas"},{"key":"BFsrep39355_CR28","first-page":"2988","volume":"31","author":"W Yue","year":"2010","unstructured":"Yue, W., Zhe, C., Jian, C. & Wei, L. Efficacy observation on recombinant human Ad- p53 injection combined with cisplatin in treating 99 cases of malignant pleural effusion (in Chinese). Guangdong Medical Journal 31, 2988\u20132990 (2010).","journal-title":"Guangdong Medical Journal"},{"key":"BFsrep39355_CR29","first-page":"695","volume":"34","author":"Z Zongyuan","year":"2013","unstructured":"Zongyuan, Z. & Xia, L. Clinical efficacy of recombinant adenovirus-p53 injection in the treatment of malignant pleural effusions (in Chinese). Sichuan Medical Journal 34, 695\u2013696 (2013).","journal-title":"Sichuan Medical Journal"},{"key":"BFsrep39355_CR30","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1186\/s12957-015-0729-9","volume":"13","author":"R Biaoxue","year":"2015","unstructured":"Biaoxue, R., Shuxia, M., Wenlong, G. & Shuanying, Y. Thoracic perfusion of matrine as an adjuvant treatment improves the control of the malignant pleural effusions. World J Surg Oncol 13, 329, doi: 10.1186\/s12957-015-0729-9 (2015).","journal-title":"World J Surg Oncol"},{"key":"BFsrep39355_CR31","doi-asserted-by":"publisher","first-page":"2193","DOI":"10.3892\/ol.2015.3054","volume":"9","author":"KL Li","year":"2015","unstructured":"Li, K. L. et al. Efficacy of recombinant adenoviral human p53 gene in the treatment of lung cancer-mediated pleural effusion. Oncol Lett 9, 2193\u20132198, doi: 10.3892\/ol.2015.3054 (2015).","journal-title":"Oncol Lett"},{"key":"BFsrep39355_CR32","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.1185\/03007995.2012.728525","volume":"28","author":"R Biaoxue","year":"2012","unstructured":"Biaoxue, R., Shuanying, Y., Wei, L., Wei, Z. & Zongjuan, M. Maintenance therapy of gefitinib for non-small-cell lung cancer after first-line chemotherapy regardless of epidermal growth factor receptor mutation: a review in Chinese patients. Curr Med Res Opin 28, 1699\u20131708, doi: 10.1185\/03007995.2012.728525 (2012).","journal-title":"Curr Med Res Opin"},{"key":"BFsrep39355_CR33","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1186\/1477-7819-10-170","volume":"10","author":"B Rong","year":"2012","unstructured":"Rong, B., Yang, S., Li, W., Zhang, W. & Ming, Z. Systematic review and meta-analysis of Endostar (rh-endostatin) combined with chemotherapy versus chemotherapy alone for treating advanced non-small cell lung cancer. World J Surg Oncol 10, 170, doi: 10.1186\/1477-7819-10-170 (2012).","journal-title":"World J Surg Oncol"},{"key":"BFsrep39355_CR34","first-page":"107","volume":"12","author":"DP Lane","year":"2011","unstructured":"Lane, D. P., Brown, C. J., Verma, C. & Cheok, C. F. New insights into p53 based therapy. Discov Med 12, 107\u2013117 (2011).","journal-title":"Discov Med"},{"key":"BFsrep39355_CR35","doi-asserted-by":"publisher","first-page":"153","DOI":"10.3779\/j.issn.1009-3419.2013.03.07","volume":"16","author":"X Zhang","year":"2013","unstructured":"Zhang, X. et al. Efficacy of recombinant adenoviral human p53 gene in treatment of malignant pleural or peritoneal effusions. Zhongguo Fei Ai Za Zhi 16, 153\u2013156, doi: 10.3779\/j.issn.1009-3419.2013.03.07 (2013).","journal-title":"Zhongguo Fei Ai Za Zhi"},{"key":"BFsrep39355_CR36","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1517\/14712598.2015.990882","volume":"15","author":"Y Li","year":"2015","unstructured":"Li, Y., Li, B., Li, C. J. & Li, L. J. Key points of basic theories and clinical practice in rAd-p53 (Gendicine) gene therapy for solid malignant tumors. Expert Opin Biol Ther 15, 437\u2013454, doi: 10.1517\/14712598.2015.990882 (2015).","journal-title":"Expert Opin Biol Ther"},{"key":"BFsrep39355_CR37","doi-asserted-by":"publisher","first-page":"1901","DOI":"10.2147\/ott.s50483","volume":"7","author":"GX Chen","year":"2014","unstructured":"Chen, G. X. et al. Clinical utility of recombinant adenoviral human p53 gene therapy: current perspectives. Onco Targets Ther 7, 1901\u20131909, doi: 10.2147\/ott.s50483 (2014).","journal-title":"Onco Targets Ther"},{"key":"BFsrep39355_CR38","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1186\/1477-7525-7-102","volume":"7","author":"A Montazeri","year":"2009","unstructured":"Montazeri, A. Quality of life data as prognostic indicators of survival in cancer patients: an overview of the literature from 1982 to 2008. Health Qual Life Outcomes 7, 102, doi: 10.1186\/1477-7525-7-102 (2009).","journal-title":"Health Qual Life Outcomes"},{"key":"BFsrep39355_CR39","doi-asserted-by":"publisher","first-page":"e96848","DOI":"10.1371\/journal.pone.0096848","volume":"9","author":"Z Hamidou","year":"2014","unstructured":"Hamidou, Z. et al. Impact of response shift on time to deterioration in quality of life scores in breast cancer patients. PLoS One 9, e96848, doi: 10.1371\/journal.pone.0096848 (2014).","journal-title":"PLoS One"},{"key":"BFsrep39355_CR40","first-page":"16","volume":"28","author":"Y Liqun","year":"2009","unstructured":"Liqun, Y., Ruilin, W., Hui, W. & Yuimei, P. P53 gene status and its therapeutic effect. Chinese and Foreign Medical 28, 16\u201317 (2009).","journal-title":"Chinese and Foreign Medical"},{"key":"BFsrep39355_CR41","doi-asserted-by":"publisher","first-page":"127","DOI":"10.3779\/j.issn.1009-3419.2006.02.06","volume":"9","author":"Z Wang","year":"2006","unstructured":"Wang, Z., Lu, B., Wang, T., De, W. & Shu, Y. Effect of recombinant adenovirus-p53 on growth and chemosensitivity of human lung adenocarcinoma cell lines. Zhongguo Fei Ai Za Zhi 9, 127\u2013131, doi: 10.3779\/j.issn.1009-3419.2006.02.06 (2006).","journal-title":"Zhongguo Fei Ai Za Zhi"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep39355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39355","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep39355.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T01:25:37Z","timestamp":1672881937000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep39355"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,12,15]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep39355"],"URL":"https:\/\/doi.org\/10.1038\/srep39355","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,12,15]]},"assertion":[{"value":"26 September 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 December 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"39355"}}